SCHEMBL6503892

SCHEMBL6503892

COc1cccc(C(C=O)c2ccncc2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ROCK2 O75116 11/20 0.47
ROCK1 Q13464 8/20 0.47
PRKG1 Q13976 8/20 0.47
PRKACA P17612 5/20 0.47
GSK3A P49840 5/20 0.47
GSK3B P49841 5/20 0.47
PRKX P51817 4/20 0.47
CLK4 Q9HAZ1 4/20 0.47
CHEK1 O14757 3/20 0.47
PRKCQ Q04759 3/20 0.47
RPS6KA5 O75582 3/20 0.47
RPS6KB1 P23443 3/20 0.47
CDK2 P24941 3/20 0.47
MAPK1 P28482 3/20 0.47
AKT2 P31751 3/20 0.47
PRKCD Q05655 3/20 0.47
PRKG2 Q13237 3/20 0.47
PKN2 Q16513 3/20 0.47
CDC42BPA Q5VT25 3/20 0.47
HIPK4 Q8NE63 3/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1515778 0.87 CHRM2 (0.48) CHRM2CHRM1CHRM3
SCHEMBL1515839 0.85 KCNA5 (0.47) CYP2D6CYP3A4CYP2C9CYP19A1CYP11B1
SCHEMBL4828431 0.84 AKR1C3 (0.47) CYP2D6CYP3A4CYP2C9CYP1A2
SCHEMBL5319843 0.82 CYP17A1 (0.53) MAPK1CYP2D6CYP3A4CYP2C9CYP19A1
SCHEMBL7450991 0.82 CHRM2 (0.47) CHRM2CHRM1CHRM3
SCHEMBL1515892 0.82 NFE2L2 (0.49) NFE2L2CHRM2CHRM1CHRM3ALDH1A1
SCHEMBL6510105 0.80 MAPKAPK2 (0.44) ROCK2CYP19A1CYP11B1CYP11B2
SCHEMBL6508159 0.77 ALDH1A1 (0.47) CYP2D6CYP2C9CYP1A1CYP1A2CYP1B1
SCHEMBL23882848 0.76 ROCK1 (0.50) ROCK2ROCK1PRKG1PRKACAGSK3A
SCHEMBL4025059 0.76 AOC3 (0.51) ROCK2ROCK1PRKG1PRKACAGSK3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050080113-A1 Medicinal compositions TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-04-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050080113-A1 Medicinal compositions TNF, TRAF6, MMP8 ROCK2 102/4885ROCK1 53/4885PRKG1 114/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.